MPB-1734 not checked
MegaPro Biomedical Co. Ltd. · DMB025
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumor, Unspecified, Adult
- Main trialPhase 1/2
- “This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.”In the company’s words, NCT04643418 on ClinicalTrials.gov
- Other names
- DMB025
Other drugs for Solid Tumor, Unspecified, Adult
- TovorafenibDay One Biopharmaceuticals, Inc. · Phase 3
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- SomapacitanNovo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Mar 2025 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026